Search for: "Bayer v. Bayer" Results 41 - 60 of 1,118
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Mar 2022, 3:49 pm
 Jane LambertPatents Court (Mr Justice Mellor) Teva Pharmaceutical Industries Ltd and another Bayer Healthcare LLC [2021] EWHC 2690 (Pat) (8 Oct 2021)This was an action for the revocation of EP (UK) 2,305,255 under s.72 (1) (a) of the Patents Act 1977:"Subject to the following provisions of this Act, the court or the comptroller may by order revoke a patent for an invention on the application of [read post]
24 Jan 2022, 1:19 am by Rose Hughes
The Board of Appeal did not agree, and found that there was no reason in the prior art for the skilled person to have rejected the use of an anti-Blys antibody as one of a number of the obvious alternatives (compare the recent UK High Court decision in Bayer v Teva on whether the selection of a formulation salt was obvious to try, IPKat). [read post]
17 Jan 2022, 1:08 am by Rose Hughes
Whilst the fact of the cases differ, the PTAB and CAFC reasoning in Teva vs Corcept is markedly different, for example, to the reasoning of the UK High Court in Bayer v Teva [2021] EWHC 2690 (Pat) (IPKat) and Actavis v ICOS (IPKat), in which inventions arising from multi-step drug development programs were found obvious-to-try in view of a known treatment effect for a particular drug, regardless of whether there was an unpredictable technical effect. [read post]
6 Jan 2022, 1:22 pm by Kevin LaCroix
  The answer to this question, at least with respect to the Bayer lawsuit, is “No. [read post]
3 Jan 2022, 12:39 pm by Kevin LaCroix
The directors’ and officers’ liability environment is always changing, but 2021 was a particularly eventful year, with important consequences for the D&O insurance marketplace. [read post]
28 Dec 2021, 1:48 am by Rose Hughes
(T 966/18) (14 July 2021)Bayer v Teva: Drug fo [read post]
28 Nov 2021, 6:58 am by Rose Hughes
 Final thoughtsThe judge's reasoning in Bayer v Teva resembles the approach taken by the UK Supreme Court in Actavis v ICOS. [read post]
27 Oct 2021, 5:15 am by Dennis Crouch
Bayer Consumer Care AG, No. 21-195 (impact of foreign use on trademark rights in the US); Australian Leather Pty. [read post]
26 Jul 2021, 3:58 am by Tian Lu
Examples of such misfortune include the ‘Aspirin’ for acetylsalicylic acid in the United States (Bayer Co. v. [read post]
13 Jul 2021, 5:51 am
In this study, we examine the impact of the gender discrimination lawsuit Pao v. [read post]